Tyrphostin AG490 AG-490 JAK-2 specific inhibitor CAS: 133550-30-8

CAS NO: 133550-30-8
Tyrphostin AG490 AG-490 JAK-2 specific inhibitor
CBNumber: CB4779212
Chemical Name: AG 490
Molecular Formula: C17H14N2O3
Formula Weight: 294.3
CAS No.: 133550-30-8
Description Review
Description

Tyrphostin AG490 (also known as AG-490) is a chemical compound that is used in scientific research as a JAK-2 specific inhibitor. This inhibition has potential applications in treating certain medical conditions related to abnormal cell growth and inflammation.

Chemical name: The chemical name of Tyrphostin AG490 is 2-(2'-chloro-4'-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide.

Molecular formula: The molecular formula of Tyrphostin AG490 is C17H14ClF2IN2O2.

Formula weight: The molecular weight of Tyrphostin AG490 is 463.66 g/mol.

CAS No: The CAS number of Tyrphostin AG490 is 133550-30-8.

Top ten keywords from Google and synonyms:

  1. JAK-2 specific inhibitor
  2. Cancer
  3. Inflammation
  4. Signal transduction
  5. Tumor cells
  6. Immune response
  7. Tyrosine kinase
  8. Leukemia
  9. Multiple myeloma
  10. Autoimmunity

Synonyms: • AG-490 • NSC 36524 • 2-(2'-Chloro-4'-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide • Tyrosine kinase inhibitor AG490

Health benefits of this product: Tyrphostin AG490 inhibits the activity of the enzyme JAK-2, which plays a role in various cellular processes like signal transduction, cell proliferation, and differentiation. By inhibiting JAK-2, Tyrphostin AG490 can potentially affect these processes, leading to changes in cell behavior, including cell cycle arrest or apoptosis. This inhibition has potential applications in treating certain medical conditions related to abnormal cell growth and inflammation, such as cancer and autoimmune diseases.

Potential effects: Tyrphostin AG490 inhibits the activity of the enzyme JAK-2, which plays a role in various cellular processes like signal transduction, cell proliferation, and differentiation. By inhibiting JAK-2, Tyrphostin AG490 can potentially affect these processes, leading to changes in cell behavior, including cell cycle arrest or apoptosis. This inhibition has potential applications in treating certain medical conditions related to abnormal cell growth and inflammation, such as cancer and autoimmune diseases.

Product mechanism: Tyrphostin AG490 inhibits the activity of the enzyme JAK-2 by binding to the ATP-binding site of the enzyme. JAK-2 is involved in various cellular processes, including signal transduction, cell proliferation, and differentiation. By inhibiting JAK-2, Tyrphostin AG490 can block these processes and potentially reduce abnormal cell growth and inflammation.

Safety: Tyrphostin AG490 is mainly used in scientific research and has not been approved for human use. Its safety in humans is not well established, and there may be potential side effects associated with its use. Individuals should seek advice from a healthcare professional before using Tyrphostin AG490.

Side effects: The potential side effects of Tyrphostin AG490 are not well-established as it is primarily used in scientific research. However, there may be potential risks associated with its use, including toxicity and effects on normal cell growth.

Dosing information: Tyrphostin AG490 is mainly used in scientific research and dosing information is determined based on the specific experiment being performed. Individuals should consult with a qualified scientist or healthcare professional for guidance on appropriate dosing.

Conclusion: Tyrphostin AG490 is a chemical compound that is commonly used in scientific research as a JAK-2 specific inhibitor. The inhibition of JAK-2 has potential applications in treating certain medical conditions related to abnormal cell growth and inflammation, such as cancer and autoimmune diseases. Although mainly used in scientific research, potential side effects and safety concerns should be taken into consideration if considering its use. Further studies are needed to determine the safety and efficacy of Tyrphostin AG490 for human use

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code